
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 8, 2016

IRIDEX CORPORATION

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

0-27598
(Commission
File Number)

77-0210467
(IRS Employer
Identification No.)

1212 Terra Bella Avenue
Mountain View, California 94043
(Address of principal executive offices, including zip code)

(650) 940-4700
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01 Regulation FD Disclosure.

On November 8, 2016, IRIDEX Corporation (the "Company") posted presentation slides in PDF format to its website (<http://www.iridex.com/>) that the Company anticipates using in conferences and meetings with industry participants, investors and other third parties.

This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Presentation slides posted on November 8, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IRIDEX CORPORATION

By: /s/ WILLIAM M. MOORE
William M. Moore
President and Chief Executive Officer

Date: November 8, 2016

EXHIBIT INDEX

Exhibit No.	Description
99.1	Presentation slides posted on November 8, 2016.



IRIDEX Corporation

November 2016

Corporate Presentation

NASDAQ: IRIX




Safe Harbor

Participation in this presentation requires that you be aware of the Federal legislation regarding forward-looking statements. Accordingly, during the course of this presentation we may make forward-looking statements regarding future events or the future performance of the Company.

We caution you that such statements are just predictions that involve risks and uncertainties, and that actual events or results could differ materially. We discuss a number of the risks in our business in detail in the Company's SEC reports, including our latest [Form 10-K](#) and our latest [Form 10-Q](#).

Investment Highlights



Surgical Retina



▲
Legacy

Medical Retina




▲
Premium Proprietary

Glaucoma



▲
Scalable Platform
Razor/Razorblade





Glaucoma: Growth Opportunity

Large Market: \$5B*

65M people with glaucoma; 17M diagnosed

Unmet Need

Significant shortcomings in current pharmaceutical and device treatment alternatives

New business model

Scalable platform: Recurring probe sales from installed base of systems




*Source: Market Scope estimate of 2015 global glaucoma treatment market excluding glaucoma diagnostic equipment



New Solutions Across the Continuum of Care

Cyclo G6™ System and associated probes



Intelligence resides in the probe, not the appliance

Revolutionary approach provides strong competitive advantage

Portfolio enables treatment along the glaucoma continuum of care

Shortcomings of Current Options


Prescription eye drops	Lasers – SLT, ALT, MLT	MIGS devices	Invasive surgery
✗ High non-compliance rates	✗ Effects dissipate over time	✗ Limited to use in cataract surgery	✗ High complication rate
✗ Complex dosing regimens	✗ High rate of failed IOP control within 12 months	✗ Incisional procedure with implant left behind	✗ High failure rate
✗ Adverse side effects	✗ Repeat procedures less effective	✗ Long term efficacy unclear	✗ Limited long-term efficacy
✗ High, recurring costs			✗ Significant post-operation patient management

Cyclo G6 Offers Compelling Solutions


- | | | | |
|------------------|-------------------|------------------|----------------------------|
| ✓ Safe | ✓ Repeatable | ✓ Titratable | ✓ Durable |
| ✓ Non-incisional | ✓ Easy to perform | ✓ Cost effective | ✓ Across continuum of care |

Cyclo G6: Immediate Commercial Impact

G6 Systems Sold*
401 Total



G6 Probes Shipped*
27,078 Total





Cyclo G6: Broad Global Support

Selected customers



CALLAHAN EYE HOSPITAL & CLINICS



America's First World's Best



UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN



40 countries have purchased with pending approvals in China and Japan

Reimbursement established with permanent U.S. CPT code

Three of six probes for G6 have been authorized by FDA



Compelling Clinical Evidence: NUHS Study – 33% IOP reduction at 18 months

MP3 Clinical Outcomes Summary at 18 Months


- ✓ 33% mean IOP reduction at 18 months
- ✓ Reduction in eye drops from mean of 2.1 to 1.3
- ✓ On average 1.3 treatments per patient with MP3 probe
- ✓ Procedure can be add-on therapy as well as monotherapy
- ✓ No adverse events

Source: Clin Experiment Ophthalmol 2010;38(3):266-72



NUHS Clinical Study

Mean IOP (n=38)





Compelling Clinical Evidence: NUHS Followup Study – 43% IOP reduction at 78 months

MP3 Clinical Outcomes Summary at 78 Months


- ✓ 43% mean IOP reduction at 78 months
- ✓ Reduction in eye drops from mean of 1.8 to 1.1
- ✓ On average 3.6 treatments per patient with MP3 probe

Source: EGS abstract, Prague, Czech Republic, June 19-22, 2016



NUHS Clinical Study


Mean IOP (n=14)



Compelling Clinical Evidence: Additional Studies Provide Consistent Outcomes


Dr. Robert Noecker MP3 Patient Case Series ¹

Mean IOP (n=46)



Wills Eye Hospital MP3 Peer Reviewed Study ²

Mean IOP (n=19)



Other MP3 studies

- Wills Eye Hospital study ³
 - Ongoing prospective study reporting 54% IOP reduction at three months (N=15)
- UC San Francisco study ⁴
 - Study demonstrating no evidence of anatomical effects from MP3
- Yale University study ⁵
 - Study demonstrating minimal tissue disruption from MP3
- Multi-Center Retrospective study ⁶
 - 30% IOP reduction at three months

¹ ARVO Abstract, Baltimore, Maryland, May 7-11, 2016

² Lasers Medical Science (2016)31:393-396, DOI 10.1007/s10103-015-1856-9


³ AGS Abstract, San Diego, CA, March 3-6, 2016

⁴ AGS Abstract, Fort Lauderdale, FL, March 2016

⁴ AGS Abstract, Fort Lauderdale, FL, March 2016

⁶ AGS Abstract, San Diego, CA, February 2015

Retina





Medical Retina: Growth Opportunity

Large Market for DME: \$9B*

Aging population and diabetes epidemic

Unmet Need

High cost of treatment and treatment burden to physicians and patients

Evolving business model


Capital equipment model transitioning to include additional revenue sources



* Source: Market Scope estimate of global retinal pharmaceutical market plus retinal laser market in 2015

MicroPulse Offers Comparable Clinical Outcomes Without Tissue Scarring

Traditional Laser




Pre-treatment




1 Year Post-treatment

Scarring clearly visible using traditional laser technology and continuous-wave laser treatment.

uP MicroPulse®



Pre-treatment



1 Year Post-treatment

Scarring non-existent with equivalent visual acuity results as traditional laser, plus increased retinal sensitivity, using MicroPulse laser therapy.



Medical Retina: Substantial Evidence Supports MicroPulse


Safety

10-year follow-up data proved no detectable retina damage.



Efficacy

Control randomized trials showed improved vision and improved retinal sensitivity.



Efficiency

More treatable patients. Improved patient pass-through rates.



Economics

Using anti-VEGF and MicroPulse may reduce treatment burden and costs.



Selected customers



Over 65 countries have purchased

Over 135 publications, posters and podium presentations


Over 700 systems sold and estimated ~1 million patients treated




Financial Snapshot as of Q3 2016

Revenue


(\$ in millions)



Revenue Mix



■ U.S. ■ O.U.S



■ Recurring ■ Systems

Balance Sheet

(\$ in millions)

Cash	\$9.5
Debt	\$0.0



* 2015 revenue impacted by supply chain issues


Near and Mid-Term Goals

- Expand US and International salesforce; further penetrate territories
- Increase manufacturing capacity; improve design and processes for scale
- Product enhancements to introduce new features and benefits

Future Programs in Development

- MicroPulse technology for other eye diseases
- Lower cost and improved reliability laser technologies
- New delivery modalities

Key Investment Highlights





Thank You



Saksonov, Poster
MicroPulse 577 Cystoid
ME due to BRVO, APVRS
2011



Mahootchi, Rethinking
Regimen for Retinal
Disease, RT 2014



Saksonov, MicroPulse 577
vs Classic ME due to BRVO
AVPRS-VRSI 2011



Gossage, 532 TxCell
MicroPulse ME due to
BRVO, RT 2014



Inagaki, MicroPulse for
ME due to BRVO, J Ophth
2014



Caskey 577 nm MicroPulse
CRVO, RP 2013



Wong, MicroPulse
abstract, ASRS 2014doc



Luttrull, Retinal Protective
Therapy Dry AMD, IOVS
2016



Luttrull, Laser
Resensitization AMD,
Retina 2015



Luttrull, Long-term safety
MicroPulse, Retina 2011



Parodi, Intravitreal
combined w grid for ME
in BRVO, BJO 2008



Luttrull, Laser for BRVO,
Retina Today 2011



Saksonov, 577 nm ARM,
RP 2011



Parodi, Subthreshold Grid
Laser 810, Ophth 2006
FRO




Video 1:
MicroPulse Technology Animation



Video 2:
Cyclo G6 Laser System Technology



Video 3:
Transscleral Cyclophotocoagulation with Cyclo G6



Video 4:
Interview with Dr. Jacky Lee at ESCRS 2015



Video 5:
Media Release on New Treatments for Glaucoma
(Chinese with English subtitles)



Video 6:
News Report Dr. Harris on IQ577 for MLT and MP3



